BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xie X, Wang CY, Cao YX, Wang W, Zhuang R, Chen LH, Dang NN, Fang L, Jin BQ. Expression pattern of epithelial cell adhesion molecule on normal and malignant colon tissues. World J Gastroenterol 2005; 11(3): 344-347 [PMID: 15637741 DOI: 10.3748/wjg.v11.i3.344] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Salomon J, Espinosa-Parrilla Y, Goulet O, Al-Qabandi W, Guigue P, Canioni D, Bruneau J, Alzahrani F, Almuhsen S, Cerf-Bensussan N, Jeanpierre M, Brousse N, Lyonnet S, Munnich A, Smahi A. A founder effect at the EPCAM locus in Congenital Tufting Enteropathy in the Arabic Gulf. Eur J Med Genet 2011;54:319-22. [PMID: 21315192 DOI: 10.1016/j.ejmg.2011.01.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
2 Si Y, Wang J, Guan J, Han Q, Hui Y. Platelet-derived growth factor induced alpha-smooth muscle actin expression by human retinal pigment epithelium cell. J Ocul Pharmacol Ther 2013;29:310-8. [PMID: 23116162 DOI: 10.1089/jop.2012.0137] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
3 Nadal C, Maurel J, Gascon P. Is there a genetic signature for liver metastasis in colorectal cancer? World J Gastroenterol 2007; 13(44): 5832-5844 [PMID: 17990349 DOI: 10.3748/wjg.v13.i44.5832] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
4 Chen J, Zhuang X, Zheng J, Yang R, Wu F, Zhang A, Fang B. Aptamer-based cell-free detection system to detect target protein. Synth Syst Biotechnol 2021;6:209-15. [PMID: 34466691 DOI: 10.1016/j.synbio.2021.07.004] [Reference Citation Analysis]
5 van Oosten M, Crane LM, Bart J, van Leeuwen FW, van Dam GM. Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool. Transl Oncol. 2011;4:71-82. [PMID: 21461170 DOI: 10.1593/tlo.10220] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
6 Dollé L, Theise ND, Schmelzer E, Boulter L, Gires O, van Grunsven LA. EpCAM and the biology of hepatic stem/progenitor cells. Am J Physiol Gastrointest Liver Physiol. 2015;308:G233-G250. [PMID: 25477371 DOI: 10.1152/ajpgi.00069.2014] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 8.6] [Reference Citation Analysis]
7 Wang A, Ramjeesingh R, Chen CH, Hurlbut D, Hammad N, Mulligan LM, Nicol C, Feilotter HE, Davey S. Reduction in membranous immunohistochemical staining for the intracellular domain of epithelial cell adhesion molecule correlates with poor patient outcome in primary colorectal adenocarcinoma. Curr Oncol 2016;23:e171-8. [PMID: 27330354 DOI: 10.3747/co.23.3028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
8 Premsukh A, Lavoie JM, Cizeau J, Entwistle J, MacDonald GC. Development of a GMP Phase III purification process for VB4-845, an immunotoxin expressed in E. coli using high cell density fermentation. Protein Expr Purif 2011;78:27-37. [PMID: 21421055 DOI: 10.1016/j.pep.2011.03.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
9 Boogerd LS, van der Valk MJ, Boonstra MC, Prevoo HA, Hilling DE, van de Velde CJ, Sier CF, Fariña Sarasqueta A, Vahrmeijer AL. Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy. Onco Targets Ther 2018;11:1655-64. [PMID: 29615840 DOI: 10.2147/OTT.S145473] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Morris JF, Sul JY, Kim MS, Klein-Szanto AJ, Schochet T, Rustgi A, Eberwine JH. Elk-1 phosphorylated at threonine-417 is present in diverse cancers and correlates with differentiation grade of colonic adenocarcinoma. Hum Pathol 2013;44:766-76. [PMID: 23114923 DOI: 10.1016/j.humpath.2012.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
11 Wenqi D, Li W, Shanshan C, Bei C, Yafei Z, Feihu B, Jie L, Daiming F. EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J Cancer Res Clin Oncol. 2009;135:1277-1285. [PMID: 19294417 DOI: 10.1007/s00432-009-0569-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
12 Du W, Ji H, Cao S, Wang L, Bai F, Liu J, Fan D. EpCAM: a potential antimetastatic target for gastric cancer. Dig Dis Sci. 2010;55:2165-2171. [PMID: 19941073 DOI: 10.1007/s10620-009-1033-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
13 Lee SJ, Chung KY, Kwon JE, Yoon SO, Kim SK. Expression of EpCAM in adenoid cystic carcinoma. Pathology 2018;50:737-41. [PMID: 30389218 DOI: 10.1016/j.pathol.2018.08.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
14 Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol. 2007;171:386-395. [PMID: 17600130 DOI: 10.2353/ajpath.2007.070152] [Cited by in Crossref: 354] [Cited by in F6Publishing: 346] [Article Influence: 23.6] [Reference Citation Analysis]
15 Kim YS, Kaidina AM, Chiang J, Yarygin KN, Lupatov AY. Cancer stem cell molecular markers verified in vivo. Biochem Moscow Suppl Ser B 2017;11:43-54. [DOI: 10.1134/s1990750817010036] [Cited by in Crossref: 9] [Article Influence: 1.8] [Reference Citation Analysis]
16 Benko G, Spajić B, Krušlin B, Tomas D. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urologic Oncology: Seminars and Original Investigations 2013;31:468-74. [DOI: 10.1016/j.urolonc.2011.03.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
17 de Cuba EMV, Kwakman R, van Egmond M, Bosch LJW, Bonjer HJ, Meijer GA, te Velde EA. Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer: Future possibilities for personalised treatment by use of biomarkers. Virchows Arch 2012;461:231-43. [DOI: 10.1007/s00428-012-1287-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
18 Zhou Y, Cheng JT, Feng ZX, Wang YY, Zhang Y, Cai WQ, Han ZW, Wang XW, Xiang Y, Yang HY, Liu BR, Peng XC, Cui SZ, Xin HW. Could gastrointestinal tumor-initiating cells originate from cell-cell fusion in vivoWorld J Gastrointest Oncol 2021; 13(2): 92-108 [PMID: 33643526 DOI: 10.4251/wjgo.v13.i2.92] [Reference Citation Analysis]
19 Cizeau J, Grenkow DM, Brown JG, Entwistle J, Macdonald GC. Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin. Journal of Immunotherapy 2009;32:574-84. [DOI: 10.1097/cji.0b013e3181a6981c] [Cited by in Crossref: 63] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
20 Peretti T, Waisberg J, Mader AMAA, de Matos LL, da Costa RB, Conceição GMDS, Lopes AC, Nader HB, Pinhal MAS. Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma: . European Journal of Gastroenterology & Hepatology 2008;20:756-65. [DOI: 10.1097/meg.0b013e3282fc2649] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
21 Lv M, Qiu F, Li T, Sun Y, Zhang C, Zhu P, Qi X, Wan J, Yang K, Zhang K. Construction, expression, and characterization of a recombinant immunotoxin targeting EpCAM. Mediators Inflamm 2015;2015:460264. [PMID: 25960617 DOI: 10.1155/2015/460264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
22 Woopen H, Pietzner K, Richter R, Fotopoulou C, Joens T, Braicu EI, Mellstedt H, Mahner S, Lindhofer H, Darb-Esfahani S, Denkert C, Sehouli J. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer. J Gynecol Oncol 2014;25:221-8. [PMID: 25045435 DOI: 10.3802/jgo.2014.25.3.221] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
23 Entwistle J, Brown JG, Chooniedass S, Cizeau J, Macdonald GC. Preclinical Evaluation of VB6-845: An Anti-EpCAM Immunotoxin with Reduced Immunogenic Potential. Cancer Biotherapy and Radiopharmaceuticals 2012;27:582-92. [DOI: 10.1089/cbr.2012.1200.271] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
24 Tang W, Huang T, Xu Z, Huang Y. Novel Mutations in EPCAM Cause Congenital Tufting Enteropathy. J Clin Gastroenterol. 2018;52:e1-e6. [PMID: 27875355 DOI: 10.1097/mcg.0000000000000739] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
25 Hentzen JEKR, de Jongh SJ, Hemmer PHJ, van der Plas WY, van Dam GM, Kruijff S. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: A narrative review. J Surg Oncol. 2018;118:332-343. [PMID: 29938400 DOI: 10.1002/jso.25106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
26 Amoury M, Kolberg K, Pham AT, Hristodorov D, Mladenov R, Di Fiore S, Helfrich W, Kiessling F, Fischer R, Pardo A, Thepen T, Hussain AF, Nachreiner T, Barth S. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model. Cancer Lett 2016;372:201-9. [PMID: 26806809 DOI: 10.1016/j.canlet.2016.01.027] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
27 Xie X, Xu Z, Cui J, Jin B. A non-stimulatory monoclonal antibody against the inhibitory immunoreceptor LAIR-1. Monoclon Antib Immunodiagn Immunother 2014;33:141-7. [PMID: 24694245 DOI: 10.1089/mab.2013.0062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
28 Suzuki K, Nakamura K, Kato K, Hamada H, Tsukamoto T. Exploration of target molecules for prostate cancer gene therapy. Prostate. 2007;67:1163-1173. [PMID: 17516570 DOI: 10.1002/pros.20613] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
29 Sithambaram D, Palanivelu S, Subramanian K, Sahoo S, Verma RS. Specific targeting of Ep-CAM in various carcinomas by novel monoclonal antibodies. Hybridoma (Larchmt) 2011;30:511-8. [PMID: 22149275 DOI: 10.1089/hyb.2011.0069] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
30 Qin D, Li D, Zhang B, Chen Y, Liao X, Li X, Alexander PB, Wang Y, Li QJ. Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. Oncoimmunology 2020;9:1806009. [PMID: 32923168 DOI: 10.1080/2162402X.2020.1806009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]